Clinical Study
Myelofibrosis-Associated Lymphoproliferative Disease: Retrospective Study of 16 Cases and Literature Review
Table 1
Clinical and biological features of myelofibrosis associated lymphoma patients.
| | N (%) |
| | Patients | 16 | | Age (years) | | | Median (range) | 62 (16–74) | | Sex | | | Male/female | 12/4 (75/25) | | Lymphoma histology | | | Low grade | 8 (50) | | MCL | 3 | | DLCL | 3 | | others | 2 | | B symptoms | | | Positive | 11 (69) | | negative | 5 | | Splenomegaly | | | yes | 8 (50) | | no | 8 (50) | | LDH level (UI/L) | | | normal | 6 (38) | | elevated | 10 (62) | | WBC count | | | median (range) (109/L) | 8.4 (3.0-20.7) | | Hb level | | | median (range) (g/dl) | 12 (8.4–15) | | platelets count | | | median (range) (109/L) | 165 (50–444) | | Dacryocytes | | | Positive/negative/na | 1/12/3 | | Leucoerythrocytic features | | | Positive/negative/na | 3/10/3 | | FLIPI | | | 0–1 | 1/5 (20) | | 1 | 4/5 (80) | | Myelofibrosis grading | | | Mild | 9 (56) | | Moderate | 6 (37) | | Severe | 1 | | lines chemotherapy | | | 1–3 lines | 15 (93) | | 3 lines | 1 | | Overall response rate | 94% | | Overall survival (months) | 72 |
|
|
DLCL: diffuse large cell lymphoma; FLIPI: follicular lymphoma international prognostic index; LDH: lactate dehydrogenase; MCL: mantle cell lymphoma; WBC: white blood cells; Hb: hemoglobin.
|
